Literature DB >> 32114202

Ending tuberculosis by 2030-Pipe dream or reality?

Jeremiah M Chakaya1, Anthony D Harries2, Guy B Marks3.   

Abstract

Tuberculosis (TB) remains a major public health threat. In 2018, an estimated 10 million people fell ill with TB and 1.5 million died of the disease. The End TB Strategy envisages an end to TB as a public health threat and has set ambitious targets to reduce TB incidence and mortality by 90% and 95%, respectively, by 2035 compared with 2015. In this paper we describe the progress that is being made towards the achievement of these targets and highlight the challenges that are hampering this progress. The development and deployment of new tools will certainly accelerate progress towards ending TB. We believe that the end of TB is realizable if there are sustained efforts to actively find TB cases, a more robust multi-sectoral approach to tackle social determinants of TB, and improved person-centred health services.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Active TB case finding; Ending TB; Tuberculosis

Mesh:

Year:  2020        PMID: 32114202     DOI: 10.1016/j.ijid.2020.02.021

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  10 in total

1.  Active case-finding policy development, implementation and scale-up in high-burden countries: A mixed-methods survey with National Tuberculosis Programme managers and document review.

Authors:  Olivia Biermann; Phuong Bich Tran; Kerri Viney; Maxine Caws; Knut Lönnroth; Kristi Sidney Annerstedt
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

2.  Reverse vaccinology approach to design a multi-epitope vaccine construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17.

Authors:  Avanthi Moodley; Abiodun Fatoba; Moses Okpeku; Thamsanqa Emmanuel Chiliza; Mthokozisi Blessing Cedric Simelane; Ofentse Jacob Pooe
Journal:  Immunol Res       Date:  2022-05-12       Impact factor: 4.505

3.  Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting.

Authors:  Conceptor Kaaba; Maria Ruperez; Barry Kosloff; Nduku Ndunda; Kwame Shanaube; Helen Ayles
Journal:  ERJ Open Res       Date:  2021-12-27

4.  Social determinants of the changing tuberculosis prevalence in Việt Nam: Analysis of population-level cross-sectional studies.

Authors:  Nicola Foster; Hai V Nguyen; Nhung V Nguyen; Hoa B Nguyen; Edine W Tiemersma; Frank G J Cobelens; Matthew Quaife; Rein M G J Houben
Journal:  PLoS Med       Date:  2022-03-18       Impact factor: 11.069

5.  QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection.

Authors:  Francesca Saluzzo; Paola Mantegani; Valeria Poletti de Chaurand; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2022-03-24       Impact factor: 16.671

6.  Influence of Public Health Services on the Goal of Ending Tuberculosis: Evidence From Panel Data in China.

Authors:  Yang Chen; Qingyu Zhou; Xinmei Yang; Peiwu Shi; Qunhong Shen; Zhaoyang Zhang; Zheng Chen; Chuan Pu; Lingzhong Xu; Zhi Hu; Anning Ma; Zhaohui Gong; Tianqiang Xu; Panshi Wang; Hua Wang; Chao Hao; Chengyue Li; Mo Hao
Journal:  Front Public Health       Date:  2022-03-04

7.  Vitamin D3 promotes autophagy in THP-1 cells infected with Mycobacterium tuberculosis.

Authors:  Yiming Wu; Xue Lin; Fuyang Song; Di Xue; Yujiong Wang
Journal:  Exp Ther Med       Date:  2022-01-25       Impact factor: 2.447

8.  Changes in newly notified cases and control of tuberculosis in China: time-series analysis of surveillance data.

Authors:  Ye-Sheng Wang; Wen-Long Zhu; Tao Li; Wei Chen; Wei-Bing Wang
Journal:  Infect Dis Poverty       Date:  2021-02-24       Impact factor: 4.520

9.  Call for more investment in cost-effective tuberculosis care.

Authors:  Ahmad Fuady
Journal:  Lancet Reg Health West Pac       Date:  2021-05-13

10.  Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China.

Authors:  Lin Qin; Fengmin Huo; Weicong Ren; Yuanyuan Shang; Cong Yao; Xuxia Zhang; Rongmei Liu; Liping Ma; Mengqiu Gao; Yu Pang
Journal:  Infect Drug Resist       Date:  2021-06-28       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.